ClouDr Group (9955) H2 2024 earnings summary

Executive summary

• FY2024 revenue fell 5.5% to RMB3,488.1m as strategic transformation reduced lower-margin value-added sales and shifted resources toward AI-driven SaaS and P2M products.

• P2M revenue reached RMB320.4m and was profitable; pharmacy SaaS prescriptions grew 43% YoY, while total gross margin edged up 0.1 percentage points to 24.7%.

Financial highlights

• Revenue was RMB3,488.1m, down 5.5% YoY; gross profit was RMB861.7m, down 5.2%, and gross margin was 24.7% versus 24.6%.

• Operating loss widened 19.7% to RMB376.1m; net loss increased 50.1% to RMB491.4m, mainly due to impairment on assets of subsidiaries proposed for disposal.

• Adjusted net loss, a non-IFRS measure, rose 54.6% to RMB116.1m; adjusted net loss margin was 3.3% versus 2.0%.

• Basic and diluted loss per share was RMB0.89 versus RMB0.60 in FY2023.

Outlook and guidance

• Priorities include strengthening hospital and pharmacy SaaS networks, expanding proprietary P2M products, investing in medical AI, growing patient and doctor users, and pursuing strategic partnerships and acquisitions.

• In hospitals, plans focus on expanding SaaS installations and monetization through targeted marketing and P2M; pharmacy plans include a wider network, richer products and services, and improved P2M profitability.

• The iloprost license is expected to add a proprietary-product revenue stream after approval and launch; no launch timing or quantified revenue guidance was stated.